Internal Medicine, Hematology & Oncology · Salt Lake City, UT
NPI
1861441974
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1950 Circle of Hope, Clinic 1a
Salt Lake City, UT, 84112
Phone (801) 585-0100
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.4M
122,695 services
Medicare patients, 2024
306
Average age 75
Drug cost, 2024
$2.6M
577 prescriptions
Company payments, 2025
$1,944
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jonathan R Whisenant was code J0185 (injection, aprepitant, 1 mg), 11,960 times for 28 patients. In total Jonathan R Whisenant billed 122,695 services in 152 codes, and Medicare paid $2.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0185 Injection, aprepitant, 1 mg | Office | 11,960 | 28 | $1.31 | $16K |
| J1930 Injection, lanreotide, 1 mg | Office | 7,920 | 13 | $38.08 | $302K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 5,200 | 21 | $4.29 | $22K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,320 | 48 | $0.09 | $205 |
| J0897 Injection, denosumab, 1 mg | Office | 2,160 | 13 | $20.74 | $45K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 1,558 | 11 | $31.47 | $49K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 950 | 20 | $0.72 | $682 |
| J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | Office | 900 | 11 | $2.66 | $2,390 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 859 | 18 | $3.39 | $2,916 |
| 85025 Blood Count | Office | 708 | 205 | $7.59 | $5,374 |
| 80053 Clinical Chemistry | Office | 649 | 190 | $10.32 | $6,701 |
| J9190 Injection, fluorouracil, 500 mg | Office | 531 | 18 | $2.16 | $1,146 |
| 99214 Office E&M - Established | Office | 495 | 180 | $90.05 | $45K |
| 96367 Intravenous Infusion, Hydration | Office | 381 | 59 | $20.87 | $7,950 |
| 96413 Chemotherapy Administration | Office | 310 | 68 | $93.68 | $29K |
By year: 2022 $1.8M for 95,105 services; 2023 $1.8M for 93,410 services; 2024 $2.4M for 122,695 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 708 | 205 | $7.59 | $5,374 |
| 80053 Clinical Chemistry | 649 | 190 | $10.32 | $6,701 |
| 82378 Clinical Chemistry | 156 | 62 | $18.45 | $2,878 |
| 86301 Immunoassay | 121 | 31 | $20.39 | $2,467 |
| 83521 Immunoassay | 84 | 19 | $16.93 | $1,422 |
| 82784 Immunoassay | 67 | 15 | $9.11 | $610 |
| 84443 Clinical Chemistry | 65 | 36 | $16.46 | $1,070 |
| 86300 Immunoassay | 57 | 12 | $20.39 | $1,162 |
| 82728 Clinical Chemistry | 48 | 40 | $13.36 | $641 |
| 84165 Clinical Chemistry | 47 | 22 | $10.53 | $495 |
Medicare prescription drug claims, 2024
In 2024, the drug Jonathan R Whisenant prescribed most often to Medicare patients was Revlimid (Lenalidomide), with 33 prescriptions and refills. In total Jonathan R Whisenant wrote 577 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | 33 | 33 | Under 11 | $553K |
| Anastrozole Generic | 28 | 82 | 11 | $490 |
| Acyclovir Generic | 27 | 27 | Under 11 | $303 |
| Prochlorperazine Maleate Generic | 27 | 27 | 17 | $332 |
| Imatinib Mesylate Generic | 26 | 26 | Under 11 | $34K |
| Ondansetron Hcl Generic | 22 | 22 | 15 | $252 |
| Tamoxifen Citrate Generic | 21 | 66 | 11 | $518 |
| Letrozole Generic | 20 | 34 | Under 11 | $428 |
| Jakafi Ruxolitinib Phosphate | 20 | 20 | Under 11 | $322K |
| Tagrisso Osimertinib Mesylate | 19 | 19 | Under 11 | $320K |
| Dexamethasone Generic | 16 | 18 | Under 11 | $693 |
| Eliquis Apixaban | 15 | 15 | Under 11 | $9,049 |
| Pantoprazole Sodium Generic | 15 | 37 | Under 11 | $119 |
| Everolimus Generic | 15 | 15 | Under 11 | $62K |
| Pomalyst Pomalidomide | 13 | 13 | Under 11 | $275K |
Brand drugs: 187 claims; generic drugs: 390 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jonathan R Whisenant $1,944 ($1,944 in general payments such as food, travel and fees) from 9 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $1,675.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 1 | $1,675 |
| Daiichi Sankyo Inc. 4568.T | 2 | $58.98 |
| Celgene Corporation BMY | 2 | $38.52 |
| GlaxoSmithKline, LLC. GSK | 2 | $37.08 |
| BeOne Medicines USA, Inc. ONC | 1 | $34.89 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $31.74 |
| Recordati_rare_diseases_inc. | 1 | $31.31 |
| Genentech USA, Inc. ROG.SW | 1 | $22.57 |
| Merck Sharp & Dohme LLC MRK | 1 | $14.06 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.